Hereditary Cancer Screening Services

Hereditary Cancer Screening

Request Test Kits

Please indicate the quantity of test kits you would like to receive, then proceed to the next page to confirm your shipping and contact information. Please note: complimentary sample kits are only available to licensed medical professionals.

HEREDITARY CANCER SCREENING

Indications Based on Personal or Family History

RARE CANCERS

1 of these cancers diagnosed at any age

Ovarian Cancer
Breast: Male Breast Cancer or Triple Negative Breast Cancer
Colorectal cancer with abnormal MSI/IHC, MSA associated histology
Endometrial cancer with abnormal MSI/IHC
10 or more gastrointestinal polyps

CANCER AT A YOUNG AGE

1 of these cancers can be diagnosed before the age of 50

Breast Cancer
Colorectal Cancer
Endometrial Cancer

MULTIPLE CANCERS

A combination of these cancers on the same side of the family

2 or more: breast, ovarian, prostate, or pancreatic cancer
2 or more: colorectal, endometrial, ovarian, gastric, pancreatic, or other cancers (IE ureter/renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas)
2 or more: melanoma or pancreatic cancer

OVARIAN CANCER

Unaffected Patient – Family History vs Hereditary Cancer

OVARIAN | Management Considerations

Hereditary Risk

Up to 63%

Possibility to begin regiment of ovarian cancer risk reducing agents
Possible screening exam with transvaginal ultrasound and CA-125
Possible enrollment in investigational screening studies between the ages of 30-35
Bilateral salpingo-oopherectomy between ages 35-40 and completion of childbearing years

Familial Risk

Up to 11%

Currently no screening guidelines exist

General Population Risk

Up to 0.7%

Currently no screening guidelines exist

ENDOMETRIAL CANCER

Unaffected Patient – Family History vs Hereditary Cancer

ENDOMETRIAL | Management Considerations

Hereditary Risk

Up to 71%

Inform Patient about endometrial cancer symptoms

Possibility of annual pelvic examination, endometrial sampling and transvaginal ultrasound between the ages of 30-35

Possibility of hysterectomy when childbearing years have been completed

Familial Risk

Up to 4%

Currently no screening guidelines exist

General Population Risk

Up to 1.6%

Currently no screening guidelines exist

BREAST CANCER

Unaffected Patient – Family History vs Hereditary Cancer

BREAST | Management Considerations

Hereditary Risk

Up to 87%

FEMALE:

Breast self-exams starting at age 18
Clinical breast exams every 6-12 months starting at age 25
Yearly breast MRI starting at age 25
Possibility to begin regimen of breast cancer risk-reducing agents
Possibility for risk-reducing mastectomy
Possibility to enroll in investigational screening study with clinical trials

MALE: Risk of developing cancer up to 6.8% by age 70

Breast self-exam starting at age 35
Yearly clinical breast exam starting at age 35

Familial Risk

Up to 40%

FEMALE:

Consider yearly screening mammogram and clinical breast exams every 6-12 months starting 10 years prior to the youngest affected family member, but not before the age of 25
Possibility of risk reduction strategies including, but not limited to, chemoprevention

MALE: Risk of developing cancer up to 1% by age 70

Currently no screening guidelines exist

General Population Risk

Up to 7.3%

FEMALE:

Breast self-exams every 1-3 years starting at age 25
Yearly clinical breast exams and screening mammography starting at age 40

MALE: Risk of developing cancer is <0.1% by age 70

Currently no screening guidelines exist

COLORECTAL CANCER

Unaffected Patient – Family History vs Hereditary Cancer

COLORECTAL | Management Considerations

Hereditary Risk

Up to 99%

Yearly colonoscopy starting as early as age 10-15
Possibility of chemoprevention with NSAIDs
Possibility of colectomy based on polyp burden and other clinical factors

Familial Risk

Up to 20%

Screening colonoscopy starting as early as age 40 or 10 years prior to the youngest diagnosis of colorectal cancer and repeated every 5-10 years based on colonoscopy findings

General Population Risk

Up to 1.9%

Screening colonoscopy starting at age 50 or a combination of other modalities including, but not limited to, stool testing and flexible sigmoidoscopy

PANCREATIC CANCER

Unaffected Patient – Family History vs Hereditary Cancer

PANCREATIC | Management Considerations

Hereditary Risk

Up to 36%

Screening exam with Magnetic Resonance Cholangiopancreatography (MRCP) or Endoscopic Ultrasound (EUS) every 1-2 years as early as age 30-35

Familial Risk

Up to 16%

Possible enrollment in clinical trial utilizing Magnetic Resonance Cholangiopancreatography (MRCP) or Endoscopic Ultrasound (EUS)

General Population Risk

Up to 0.5%

Currently no screening guidelines exist

PROSTATE CANCER

Unaffected Patient – Family History vs Hereditary Cancer

PROSTATE | Management Considerations

Hereditary Risk

Up to 83%

Yearly prostate screening starting at the age of 45

Familial Risk

Up to 6%

Inform about familial risk concerning importance of screening exam with Digital Rectal Exam (DRE) and monitoring Prostate Specific Antigen (PSA) starting at age 45

General Population Risk

Up to 0.6%

Inform about benefits of screening with Digital Rectal Exam (DRE) and Prostate Specific Antigen (PSA) starting at age 45

TruGenX Hereditary Cancer Screening

	Breast	Ovarian	Colorectal	Uterine	Melanoma	Pancreatic	Gastric	Prostate
APC			X			X	X
ATM	X					X
AXIN2
BARDI	X
BLM
BMPR1A			X			X	X
BRCA1	X	X				X		X
BRCA2	X	X			X	X		X
BRIP1		X
CDH1	X	X	X				X
CDK4					X	X
COKN2A					X	X
CHEK2	X	X	X
EPCAM			X	X		X	X	X
GALNT12			X
GREM1			X
HOXB13							X	X
MLH1			X	X		X	X	X
MLH2			X	X		X	X	X
MLH3
MLH6			X	X		X	X	X
MUTYH			X
NBN	X	X						X
NTHL1
PALB2	X	X				X
P1K3R1
PMS2			X	X		X	X	X
POLD1			X
POLE			X
PTEN	X	X	X	X	X
RAD51C		X
RAD51D		X
RNF43
RPS20			X
SMAD2
SMAD4			X			X	X
STK11	X	X	X	X		X	X
TP53	X	X	X	X	X	X	X	X

Hereditary Cancer Screening